NAMS
$28.94-1.52 (-4.99%)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhib...
Recent News
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.
The Bull Case For NewAmsterdam Pharma (NAMS) Could Change Following 2025 Results And New Share Offering
In February 2026, NewAmsterdam Pharma reported full-year 2025 sales of US$22.50 million and a net loss of US$203.82 million, while also filing an omnibus shelf registration to offer 5,719,966 common shares. At the same time, analysts highlighted management’s confidence in the late-stage obicetrapib program and a potentially accelerated European launch pathway, reinforcing interest in the company’s cardiovascular pipeline. We’ll now examine how management’s confidence in obicetrapib’s Phase...
NewAmsterdam Pharma CFO Teases Mid-Year PREVAIL Trial Timeline Update at Guggenheim Biotech Summit
NewAmsterdam Pharma (NASDAQ:NAMS) Chief Financial Officer Ian Somaiya said the company remains encouraged by early observations from its PREVAIL cardiovascular outcomes trial and reiterated plans to provide a mid-year update on study timelines during remarks at Guggenheim’s 2026 Emerging Outlook Bio
Assessing NewAmsterdam Pharma (NAMS) Valuation After Recent Share Price Volatility
NewAmsterdam Pharma (NAMS) is back on investors’ radar after recent trading left the stock at $31.86, with mixed short term returns and a much stronger 1 year and 3 year track record. See our latest analysis for NewAmsterdam Pharma. Recent trading has been choppy, with a 1 day share price return of a 2.54% decline and a 30 day share price return of a 14.47% decline. However, the 3 year total shareholder return of 222.8% points to momentum that has built over a longer horizon. If NewAmsterdam...
NewAmsterdam Pharma Company N.V. (NAMS) Shares Spiked by 57% in Q3
TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fund returned 2.26% (gross) and 2.01% (net), compared to the Russell 2000 Growth Index’s 12.19% return. During the quarter, all asset classes except […]